Worcester-based RXi Pharmaceuticals Corp. announced results of a Phase 2 study of its NeuVax breast cancer vaccine that it said demonstrate the therapy’s promise.
NeuVax was developed by Arizona-based biotechnology firm Apthera Inc., which RXi acquired in April.
RXi said the trials enrolled 182 patients who received the vaccine once a month for six months, and then got booster shots every six months.
At 36 months, the treated groups showed no recurrences of cancer, compared to a 22-percent recurrence rate in a control group.
RXi said it plans to begin a Phase 3 trial of the vaccine in the first half of 2012.
